7. Company Strategies of Global R&D Collaborations: From West Meets West to West Meets East

“The success of our FIPNet strategy is inextricably tied to the success of our partners, and our network is only as strong as our partners.”

—John Lechleiter, CEO, Eli Lilly and Company1

Global Biopharma Industry Changes As It Interfaces with New Players

The biopharma industry used to be a club of companies from the United States, Europe, and Japan. Those companies are often classified into distinctive groups. The most important group is the so-called “big pharma,” the top dozen or so truly big global players. The second group includes the smaller “mid pharma” companies. The generics companies and the newly arrived large biotechnology (biologics) companies ...

Get The New Players in Life Science Innovation: Best Practices in R from Around the World now with O’Reilly online learning.

O’Reilly members experience live online training, plus books, videos, and digital content from 200+ publishers.